Many celebrities, who have been dramatic conversions, have avoided to accept weight loss drugs despite their growing popularity.

Addressing this reluctance, Vikrant Shrotriya, Corporate Vice President and Managing Director of Novo Nordisk India, said, “They just want to pat their backs that they have a great gene. But losing weight is never easy, and it is never easy to achieve it.

Today, during a session on the treatment of obesity in India, the Conclave on 2025, Shrotriya said that weight loss drug is a long -term drug for any metabolic disease, in which one loses weight.

Addressing concerns about reports of severe side effects of weight -loss drug, Vikrant said that the drug has passed through a rigorous evaluation process.

“It is important to understand how a drug reaches the market. It undergoes rigorous evaluation through phase 1, step 2, and step 3 tests to assess its safety and effectiveness. A drug is approved only when the benefits overtake the risks,” Vikrant explained.

He said, “We have a security monitoring through regular audit reports. After the launch it was launched, we were surprised because there was much more demand than what we demand.”

He also said that some patients may require supplements with weight loss drugs.

“Not all patients are the same. Some may lack B-complex and require supplements, while others may have osteoporosis. Obesity rarely is present in isolation, often with other comorid conditions. About 50% of obesity also have high blood pressure, and many may have osteogenesis or diabetics.

For people with comoridrities, a weight -loss drug is never a standalone solution. “In some cases, nutrition dose may be necessary as part of the treatment plan,” he said.

Novo Nordisk produces popular weight-loss drug vegovi, and its type 2 diabetes drug ozmpic.